Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

Gilead to buy YM BioSciences for about $465 million

December 12, 2012 11:06 am by | 0 Comments

(Reuters) - Gilead Sciences Inc will buy Canada's YM BioSciences Inc for about $465 million to gain access to its blood and immune cell disorder drugs.

Gilead said it will pay $2.95 per YM share.

YM shares closed at C$1.66 on Tuesday on the Toronto Stock Exchange.

(Reporting by Adithya Venkatesan and Shounak Dasgupta in Bangalore; Editing by Roshni Menon)


Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.